Judith Greciet joins from Eisai France, a company she managed as President for 3 years. Eisai France, with a €120 million turnover, is focused on high value products in the Alzheimer’s disease, a field in which it is one of the world leaders.
Judith Greciet has an exemplary career in the pharmaceutical industry and international groups. Aged 41, she holds a doctorate of pharmacy in addition to being a graduate of 3rd cycle management and pharmaceutical marketing.
Judith Greciet joined Eisai France in June 2007 after successful achievements at Wyeth Pharmaceuticals France (today Pfizer), LFB Group (“Laboratoire Français du fractionnement et des Biotechnologies”, a French bio-pharmaceutical company), Zeneca and Pharmacia, where she hold increasing operational and strategic positions involving a managerial scope. She particularly focused on optimizing links with all health actors (researchers, academic practitioners, medical doctors, patient associations, health authorities…). She exercised her talents in the oncology and immunology areas with innovative products such as Enbrel (in rheumatology). She has served successively as Head of the Oncology Department and of the Hospital Department where she was notably in charge of hospital antibiotherapy projects. Dominique Costantini, co-founder and Chief Executive Officer of BioAlliance Pharma explains: “As Deputy Chief Operating Officer, Judith Greciet represents the entry of a new generation in the drug industry. She will focus on BioAlliance’s operations and coordinate the development activities of the Company. Thanks to her expertise, she will also contribute to implement new partnerships and to define the Company’s strategic orientations. Judith will as well collaborate to the relationships with the financial community. We are delighted to welcome her and are looking forward to this next phase of the development of BioAlliance Pharma”.
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio: Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries, in Korea and in the United States Setofilm® (prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries Sitavir™ (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results AMEP® (invasive melanoma): Phase I Clonidine LauriadTM (mucositis): Phase II Doxorubicin Transdrug® (liver cancer): Phase II For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA Dominique Costantini, CEO Tel.: +33 1 45 58 76 01 dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com
ALIZE RP Caroline Carmagnol Tel.: +33 6 64 18 99 59 caroline@alizerp.com
